Skip to content
HCN Grants Est. 2026
No. HT942526TERPIIRA · Defense Health Agency Contracting Activity - DHACA
Open

DoW Toxic Exposures Investigator Initiated Research Award

Dealbreakers No cost share required Audit: not stated Reimbursement-only: not stated

At a glance

This program funds research on diseases or conditions linked to military-related toxic exposures, from basic lab work through translational and clinical research, but it does not allow clinical trials. It is open to eligible U.S. Department of War organizations, including foreign and domestic, for-profit and nonprofit, and public or private entities; independent investigators at all career levels may be named as principal investigator, but mentees such as postdoctoral or clinical fellows may not. The program expects to fund about three awards with a total cost cap of $800,000 each, over a maximum period of 3 years, and cost sharing is not required. There are no geographic restrictions stated, but applications must fit at least one program goal and one topic area, and studies on classified research, biological select agents or toxins, Havana Syndrome, directed energy weapons, and immediate point-of-injury countermeasures or treatments are not allowed.

AI-generated summary — verify against the announcement

What it funds

  • Science and Technology and other Research and Development
  • Research & Discovery
  • Patients & People with Health Conditions
  • Veterans, Military & Public-Safety Personnel
  • Biomedical & Disease Research
Official description from grants.gov

Summary: The fiscal year 2026 Toxic Exposures Research Program (TERP) Investigator-Initiated Research Award (IIRA) is intended to support studies that will make an important contribution toward research and/or patient care for diseases or conditions associated with military-related toxic exposures. Research projects may focus on any phase of research from basic laboratory research through translational research, including preclinical studies in animal models and human subjects, as well as correlative studies associated with an existing clinical trial. New Approach Methodologies may also be used. https://cdmrp.health.mil/pubs/press/2026/terppreann

Who can apply

  • Unrestricted
Geographic restriction None found in the announcement — likely nationwide